Our research findings have been published in several respected academic journals, and we have submitted a number of international patent applications. These developments have been noticed and reported on by a variety of media outlets, both local and international, such as Science Daily, Xinhua News Agency, ScienceNet.cn, China News Service, Los Angeles Times, and Australian Associated Press.
iCamuno Biotherapeutics: Utilizing Three Platforms to Improve iPSC Differentiation Efficiency
2022.08.18MORE
Efficient Advancement of iCamuno Biotherapeutics: Completing Three Rounds of Financing in Its First Year
2022.03.31MORE
Interpretation of Fate Therapeutics’ Latest ASH Data and Discussion on Future Development Trend of the iPSC Field - an Exclusive Interview with Dr. Liu Xiaodong
2022.01.06MORE
iCamuno Biotherapeutics’ Research Results are Selected as One of ‘Science’s Top 10 Scientific Breakthroughs of 2021’
2022.01.06MORE
Pumis and iCamuno Reach Strategic Cooperation to Develop Two Universal iPSC-CAB-NK Cell Therapy Products
2021.06.14MORE
A Milestone Achievement in the iPSC Field - Liu Xiaodong and Others Have Constructed the First Complete Human Embryo Model Using Somatic Cell Reprogramming Technology
